On July 8, 2013, Dr. Carlos Santos was appointed as our Chief Executive Officer. Since 2009, Dr. Santos has managed all key aspects of our personalized immunotherapy platform, including our clinical and regulatory affairs, while also leading the development of our manufacturing systems essential to personalized cancer vaccine production. He designed and led the transition of the company’s vaccine manufacture into an automated process by developing software for automated systems integral to autologous vaccine manufacture. Dr. Santos has authored numerous peer-reviewed publications in the fields of active immunotherapy, oncology, and bioinformatics. He is a graduate of the University of Michigan, where he earned a Ph.D. in Bioinformatics, and Washington University (St. Louis), where he earned a B.S. in Computer Science. At the University of Michigan, Dr. Santos developed automated natural language processing systems to integrate high-throughput genomic experimental data with known protein interaction pathways in metastatic prostate cancer progression. He also led the development of a large-scale automated search and summarization engines for biomedical documents at the University of Michigan’s National Center for Integrative Biomedical Informatics. From 1998 to 2001, Dr. Santos was a researcher at Washington University’s Institute for Biomedical Computing (now the Center for Computational Biology).